Immunotherapy, and particularly, the inhibition of the programme death 1 (PD-1)/PD-1 ligand (PD-L1) pathway, has arisen as a successful strategy to treat several cancers types [1,2,3,4,5,6,7]. The gene discussed is CD274; the disease is cancer.